{"url": {"canonical": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "__typename": "URL"}, "__typename": "Content", "id": "/content/2tu5b8a8bd3f8lnhtveg9h5v806igul1", "tegID": "2tu5b8a8bd3f8lnhtveg9h5v806igul1", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "Big pharma can\u2019t get enough of one class of cancer drugs", "subheadline": "Missile stockpiles", "seoPageTitle": null, "seoMetadataDescription": null, "ad": {"grapeshot": {"channels": null, "__typename": "Grapeshot"}, "__typename": "Ad"}, "audio": {"main": null, "__typename": "Media"}, "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBP502.jpg", "__typename": "URL"}, "__typename": "Content", "height": 720, "width": 1280, "description": "Enhertu Packaging, stack of boxes."}, "promo": null, "__typename": "Media"}, "description": "A spate of dealmaking suggests high expectations for antibody-drug conjugates", "datePublished": "2023-09-21T12:51:46Z", "dateModified": "2023-09-21T12:51:48Z", "dateRevised": "2023-09-21T12:51:48Z", "dateRevisedString": "Sep 21st 2023", "datePublishedString": "Sep 21st 2023", "dateCreated": "2023-09-20T10:54:51Z", "copyrightYear": 2023, "inLanguage": "en", "byline": "", "dateline": "New York", "topic": null, "text": [{"type": "tag", "name": "p", "attribs": {}, "children": [{"type": "tag", "name": "span", "attribs": {"data-caps": "initial"}, "children": [{"data": "A", "type": "text"}]}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ROUND THE", "type": "text"}]}, {"data": " world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "AI", "type": "text"}]}, {"data": " in their name. Another, less obvious one, involves a less catchy initialism: ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s. ", "type": "text"}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"data": "Makers of these antibody-drug conjugates, to give them their full name, are all the rage among the world\u2019s biggest drugmakers. Pfizer is paying $43bn for Seagen, which in turn has just teamed up with Nurix Therapeutics, a smaller biotechnology firm, to work on this class of drugs. Amgen, AstraZeneca and Merck have also placed billion-dollar bets on ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s. In the past five years licensing deals worth $60bn have been signed for such therapies. The number of such deals tripled in that period, to 26. So far this year 18 have been signed, outpacing similar deals involving other emerging cancer drugs.", "type": "text"}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s aren\u2019t new. The first was approved in 2000 for types of leukaemia. They act like guided biological missiles: a payload of toxic chemotherapy is carried by antibodies able to seek out cancer cells directly. Because they bypass normal tissue and go straight for their targets, they let patients receive higher doses that would otherwise cause too much collateral damage. ", "type": "text"}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"data": "Two developments explain the frenzied stockpiling of these anti-cancer weapons of late. One is increased clinical confidence. Enhertu, an ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": " developed by AstraZeneca and Daiichi Sankyo, a Japanese biotechnology company, was first approved in America in 2019. But after another set of trials in 2022 showed that it allowed breast-cancer patients to live almost twice as long without relapse as those treated with standard chemotherapy, its approval was extended to different types of breast and lung cancer. Regulators have cleared a dozen other ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s, which are now routinely used to treat some of the deadliest cancers, including leukaemia, lymphoma and breast cancer. ", "type": "text"}]}, {"type": "tag", "name": "figure", "attribs": {"itemtype": "https://schema.org/ImageObject"}, "children": [{"type": "tag", "name": "img", "attribs": {"src": "https://www.economist.com/media-assets/image/20230923_WBC663.png", "data-teg-id": "nluptg7ha9ig9evdd4qjjrm1qd5oo3do", "data-slim": "1", "height": "662", "width": "608"}, "children": []}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"data": "More than 140 new ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s are currently in clinical trials. Bristol Myers Squibb and Sanofi all have therapies in late-stage tests. AstraZeneca and Merck have each formed a joint-venture with biotech firms in China, to take advantage of Chinese regulators\u2019 more relaxed rules for early-stage trials, which helps accelerate the drugs\u2019 development. Susan Galbraith, who oversees oncology research and development at AstraZeneca, says that the timeline for drug testing in China has been significantly reduced in the past decade. ", "type": "text"}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"data": "Clinical success has, in turn, boosted commercial confidence. Sales of Enhertu exceeded $1.2bn in 2022. Revenue from Trodelvy, a similar drug approved for advanced breast cancer and sold by Gilead Sciences, rose by 79% last year, to $680m. Kadcyla brought in $1.1bn for its Swiss developer, Roche, in the first half of this year. Evaluate, a provider of health-care data, forecasts that ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": " sales could reach nearly $30bn by 2028, up from around $7.5bn last year (see chart). ", "type": "text"}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"data": "Some of these wagers could misfire. It is unclear just how well the drugs will work in combination with others, such as immunotherapies. They are also complex to make. Any deals involving Chinese partners could unravel if Sino-Western tensions increase. For now, though, ", "type": "text"}, {"type": "tag", "name": "small", "attribs": {}, "children": [{"data": "ADC", "type": "text"}]}, {"data": "s are a global arms race worth cheering. ", "type": "text"}, {"type": "tag", "name": "span", "attribs": {"data-ornament": "ufinish"}, "children": [{"data": "\u25a0", "type": "text"}]}]}, {"type": "tag", "name": "p", "attribs": {}, "children": [{"type": "tag", "name": "i", "attribs": {}, "children": [{"data": "To stay on top of the biggest stories in business and technology, sign up to the ", "type": "text"}, {"type": "tag", "name": "a", "attribs": {"href": "https://www.economist.com/newsletters/the-bottom-line"}, "children": [{"data": "Bottom Line", "type": "text"}]}, {"data": ", our weekly subscriber-only newsletter.", "type": "text"}]}]}], "bodyText": "AROUND THE world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with AI in their name. Another, less obvious one, involves a less catchy initialism: ADCs. \nMakers of these antibody-drug conjugates, to give them their full name, are all the rage among the world\u2019s biggest drugmakers. Pfizer is paying $43bn for Seagen, which in turn has just teamed up with Nurix Therapeutics, a smaller biotechnology firm, to work on this class of drugs. Amgen, AstraZeneca and Merck have also placed billion-dollar bets on ADCs. In the past five years licensing deals worth $60bn have been signed for such therapies. The number of such deals tripled in that period, to 26. So far this year 18 have been signed, outpacing similar deals involving other emerging cancer drugs.\nADCs aren\u2019t new. The first was approved in 2000 for types of leukaemia. They act like guided biological missiles:  a payload of toxic chemotherapy is carried by antibodies able to seek out cancer cells directly. Because they bypass normal tissue and go straight for their targets, they let patients receive higher doses that would otherwise cause too much collateral damage. \nTwo developments explain the frenzied stockpiling of these anti-cancer weapons of late. One is increased clinical confidence. Enhertu, an ADC developed by AstraZeneca and Daiichi Sankyo, a Japanese biotechnology company, was first approved in America in 2019. But after another set of trials in 2022 showed that it allowed breast-cancer patients to live almost twice as long without relapse as those treated with standard chemotherapy, its approval was extended to different types of breast and lung cancer. Regulators have cleared a dozen other ADCs, which are now routinely used to treat some of the deadliest cancers, including leukaemia, lymphoma and breast cancer. \n\nMore than 140 new ADCs are currently in clinical trials. Bristol Myers Squibb and Sanofi all have therapies in late-stage tests. AstraZeneca and Merck have each formed a joint-venture with biotech firms in China, to take advantage of Chinese regulators\u2019 more relaxed rules for early-stage trials, which helps accelerate the drugs\u2019 development. Susan Galbraith, who oversees oncology research and development at AstraZeneca, says that the timeline for drug testing in China has been significantly reduced in the past decade. \nClinical success has, in turn, boosted commercial confidence. Sales of Enhertu exceeded $1.2bn in 2022. Revenue from Trodelvy, a similar drug approved for advanced breast cancer and sold by Gilead Sciences, rose by 79% last year, to $680m. Kadcyla brought in $1.1bn for its Swiss developer, Roche, in the first half of this year. Evaluate, a provider of health-care data, forecasts that ADC sales could reach nearly $30bn by 2028, up from around $7.5bn last year (see chart). \nSome of these wagers could misfire. It is unclear just how well the drugs will work in combination with others, such as immunotherapies. They are also complex to make. Any deals involving Chinese partners could unravel if Sino-Western tensions increase. For now, though, ADCs are a global arms race worth cheering. \u25a0\nTo stay on top of the biggest stories in business and technology, sign up to the Bottom Line, our weekly subscriber-only newsletter.", "about": {"public": null, "__typename": "Taxonomies"}, "print": {"headline": "Dealing with cancer", "section": {"url": {"canonical": "https://www.economist.com/business/", "__typename": "URL"}, "__typename": "Content", "headline": "Business"}, "__typename": "Print"}, "articleSection": {"public": null, "internal": [{"url": {"canonical": "https://www.economist.com/business/", "__typename": "URL"}, "__typename": "Content", "id": "/content/79244csej12lltat5mgqtckdp41aagcj", "tegID": "79244csej12lltat5mgqtckdp41aagcj", "headline": "Business", "hasPart": {"parts": [{"url": {"canonical": "https://www.economist.com/business/2023/09/21/abu-dhabi-throws-a-surprise-challenger-into-the-ai-race", "__typename": "URL"}, "__typename": "Content", "id": "/content/b4p157fqc1oeop2urucv1cpd4clks1ub", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "Abu Dhabi throws a surprise challenger into the AI race", "subheadline": "Can Falcon soar?", "datePublished": "2023-09-21T12:51:46Z", "description": "It has released the world\u2019s most powerful open-source model, and will soon launch an AI company", "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBD003.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 720}, "__typename": "Media", "promo": null}}, {"url": {"canonical": "https://www.economist.com/business/2023/09/21/california-cracks-down-on-carbon", "__typename": "URL"}, "__typename": "Content", "id": "/content/1o2shmegq6c5r1aq48mi068593bb9brb", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "California cracks down on carbon", "subheadline": "Emissionary zeal", "datePublished": "2023-09-21T12:51:46Z", "description": "It is not just attacking big oil. Big everything is in the line of fire", "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBP002.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 720}, "__typename": "Media", "promo": null}}, {"url": {"canonical": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "__typename": "URL"}, "__typename": "Content", "id": "/content/2tu5b8a8bd3f8lnhtveg9h5v806igul1", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "Big pharma can\u2019t get enough of one class of cancer drugs", "subheadline": "Missile stockpiles", "datePublished": "2023-09-21T12:51:46Z", "description": "A spate of dealmaking suggests high expectations for antibody-drug conjugates", "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBP502.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 720}, "__typename": "Media", "promo": null}}, {"url": {"canonical": "https://www.economist.com/business/2023/09/21/friendships-in-the-office", "__typename": "URL"}, "__typename": "Content", "id": "/content/fh82aprub7qprnmv9tmsv8qket7i8m5g", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "Friendships in the office", "subheadline": "Bartleby", "datePublished": "2023-09-21T12:51:46Z", "description": "Friends make employees more engaged. That\u2019s no reason for companies to get involved", "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBD004.jpg", "__typename": "URL"}, "__typename": "Content", "width": 608, "height": 630}, "__typename": "Media", "promo": null}}, {"url": {"canonical": "https://www.economist.com/business/2023/09/21/what-arm-and-instacart-say-about-the-coming-ipo-wave", "__typename": "URL"}, "__typename": "Content", "id": "/content/2urnd2kkds2latc8pp0tvp8a9ilp7iua", "type": ["Article", "NewsArticle", "AnalysisNewsArticle"], "headline": "What Arm and Instacart say about the coming IPO wave", "subheadline": "Schumpeter", "datePublished": "2023-09-21T09:29:57Z", "description": "The old-school stockmarket debut is back. About time", "image": {"main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_WBD002.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 720}, "__typename": "Media", "promo": null}}], "__typename": "HasPart"}}], "__typename": "Taxonomies"}, "publication": [{"url": {"canonical": "https://www.economist.com/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "tegID": "q7kadojabt8mqss3838etdaslph43q0e", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}, {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_AP.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Investing in the neighbourhood: Asia\u2019s new model of regional integration", "width": 1280, "height": 1684, "regionsAllowed": ["AF", "AS", "AU", "BD", "BT", "BN", "KH", "CN", "CK", "FJ", "GU", "PF", "HK", "IN", "ID", "JP", "KI", "KP", "KR", "LA", "MO", "MY", "MV", "MH", "FM", "MN", "MM", "NR", "NP", "NC", "NZ", "PK", "PG", "PH", "PN", "SC", "SG", "SB", "LK", "TF", "TW", "TH", "TO", "TV", "VU", "VN", "IO", "CC", "TL", "HM", "NU", "NF", "MP", "PW", "WS", "CX", "TK", "WF"]}, {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_UK.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["UK", "GB", "GG", "IM", "JE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_AP.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}, {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_UK.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/eu/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "tegID": "3et857aqlkhdb2sjdnaq7cvei52kc0nl", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/ap/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "tegID": "kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_AP.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Investing in the neighbourhood: Asia\u2019s new model of regional integration", "width": 1280, "height": 1684, "regionsAllowed": ["AF", "AS", "AU", "BD", "BT", "BN", "KH", "CN", "CK", "FJ", "GU", "PF", "HK", "IN", "ID", "JP", "KI", "KP", "KR", "LA", "MO", "MY", "MV", "MH", "FM", "MN", "MM", "NR", "NP", "NC", "NZ", "PK", "PG", "PH", "PN", "SC", "SG", "SB", "LK", "TF", "TW", "TH", "TO", "TV", "VU", "VN", "IO", "CC", "TL", "HM", "NU", "NF", "MP", "PW", "WS", "CX", "TK", "WF"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_AP.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_AP.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/la/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "tegID": "4bq6lktc4ae95v69i85aafs6o870pm2u", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/me/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "tegID": "34hc4rj8qmujur479tl3n4os4616096t", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/uk/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "tegID": "dg3g5stcnd95p2l8a25396rfsk62i042", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_UK.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["UK", "GB", "GG", "IM", "JE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_UK.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_UK.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/na/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "tegID": "lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}, {"url": {"canonical": "https://www.economist.com/a/printedition/2023-09-23", "__typename": "URL"}, "__typename": "Content", "type": ["PublicationIssue", "RegionalIssue"], "headline": "WEEKLY EDITION: SEPT 23RD", "description": "", "subheadline": "", "datePublished": "2023-09-23T00:00:00Z", "datePublishedString": "Sep 23rd 2023", "id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "tegID": "9rk0h3dl3sggbqj9nis863hduia265ve", "image": {"cover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "headline": "Time for a rethink: Helping Ukraine win a long war", "width": 1280, "height": 1684, "regionsAllowed": ["AD", "AL", "AM", "AX", "AZ", "BA", "BG", "BY", "CH", "CY", "CZ", "EE", "FO", "GE", "GI", "GL", "HR", "HU", "IS", "KG", "KZ", "LI", "LT", "LV", "MC", "MD", "ME", "MK", "MT", "NO", "PL", "RO", "RS", "RU", "SI", "SJ", "SK", "SM", "TJ", "TM", "TR", "UA", "UZ", "VA", "IT", "FR", "ES", "IE", "AT", "BE", "DK", "FI", "DE", "GR", "LU", "NL", "PT", "SE", "US", "CA", "PM", "UM", "AI", "BL", "BQ", "BV", "CW", "GS", "MF", "SX", "AG", "AR", "AW", "BS", "BB", "BZ", "BM", "BO", "BR", "KY", "CL", "CO", "CR", "CU", "DM", "DO", "EC", "SV", "FK", "GF", "GD", "GP", "GT", "GY", "HN", "HT", "JM", "MQ", "MX", "MS", "NI", "PA", "PY", "PE", "PR", "KN", "LC", "VC", "SR", "TT", "TC", "UY", "VE", "VG", "VI", "DZ", "AO", "BJ", "BW", "BF", "BI", "CM", "CV", "CF", "TD", "KM", "CD", "CI", "DJ", "EG", "GQ", "ER", "ET", "GA", "GM", "GH", "GN", "GW", "KE", "LS", "LR", "LY", "MG", "MU", "MW", "ML", "MR", "YT", "MA", "MZ", "NA", "NE", "NG", "RE", "RW", "SH", "SS", "ST", "SN", "SL", "SO", "ZA", "SD", "SZ", "TZ", "TG", "TN", "UG", "EH", "ZM", "ZW", "CG", "BH", "IR", "IQ", "IL", "JO", "KW", "LB", "OM", "SA", "SY", "AE", "PS", "QA", "YE"]}], "main": {"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1684}, "squareCover": [{"url": {"canonical": "https://www.economist.com/media-assets/image/20230923_DE_SQ_US.jpg", "__typename": "URL"}, "__typename": "Content", "width": 1280, "height": 1280}], "__typename": "Media"}}], "channel": {"tegID": "j53t6hsedat4l7rkbb1le98u73262sh5", "__typename": "Content"}, "_metadata": {"articleId": "/content/2tu5b8a8bd3f8lnhtveg9h5v806igul1", "tegID": "2tu5b8a8bd3f8lnhtveg9h5v806igul1", "title": "Missile stockpiles - Big pharma can\u2019t get enough of one class of cancer drugs | Business | The Economist", "shareSnippet": "Missile stockpiles \u2013 Big pharma can\u2019t get enough of one class of cancer drugs", "headline": "Big pharma can\u2019t get enough of one class of cancer drugs", "section": "Business", "keywords": [], "author": ["The Economist"], "url": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "type": "Article", "articleBody": "AROUND THE world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with AI in their name. Another, less obvious one, involves a less catchy initialism: ADCs. \nMakers of these antibody-drug conjugates, to give them their full name, are all the rage among the world\u2019s biggest drugmakers. Pfizer is paying $43bn for Seagen, which in turn has just teamed up with Nurix Therapeutics, a smaller biotechnology firm, to work on this class of drugs. Amgen, AstraZeneca and Merck have also placed billion-dollar bets on ADCs. In the past five years licensing deals worth $60bn have been signed for such therapies. The number of such deals tripled in that period, to 26. So far this year 18 have been signed, outpacing similar deals involving other emerging cancer drugs.\nADCs aren\u2019t new. The first was approved in 2000 for types of leukaemia. They act like guided biological missiles:  a payload of toxic chemotherapy is carried by antibodies able to seek out cancer cells directly. Because they bypass normal tissue and go straight for their targets, they let patients receive higher doses that would otherwise cause too much collateral damage. \nTwo developments explain the frenzied stockpiling of these anti-cancer weapons of late. One is increased clinical confidence. Enhertu, an ADC developed by AstraZeneca and Daiichi Sankyo, a Japanese biotechnology company, was first approved in America in 2019. But after another set of trials in 2022 showed that it allowed breast-cancer patients to live almost twice as long without relapse as those treated with standard chemotherapy, its approval was extended to different types of breast and lung cancer. Regulators have cleared a dozen other ADCs, which are now routinely used to treat some of the deadliest cancers, including leukaemia, lymphoma and breast cancer. \n\nMore than 140 new ADCs are currently in clinical trials. Bristol Myers Squibb and Sanofi all have therapies in late-stage tests. AstraZeneca and Merck have each formed a joint-venture with biotech firms in China, to take advantage of Chinese regulators\u2019 more relaxed rules for early-stage trials, which helps accelerate the drugs\u2019 development. Susan Galbraith, who oversees oncology research and development at AstraZeneca, says that the timeline for drug testing in China has been significantly reduced in the past decade. \nClinical success has, in turn, boosted commercial confidence. Sales of Enhertu exceeded $1.2bn in 2022. Revenue from Trodelvy, a similar drug approved for advanced breast cancer and sold by Gilead Sciences, rose by 79% last year, to $680m. Kadcyla brought in $1.1bn for its Swiss developer, Roche, in the first half of this year. Evaluate, a provider of health-care data, forecasts that ADC sales could reach nearly $30bn by 2028, up from around $7.5bn last year (see chart). \nSome of these wagers could misfire. It is unclear just how well the drugs will work in combination with others, such as immunotherapies. They are also complex to make. Any deals involving Chinese partners could unravel if Sino-Western tensions increase. For now, though, ADCs are a global arms race worth cheering. \u25a0\nTo stay on top of the biggest stories in business and technology, sign up to the Bottom Line, our weekly subscriber-only newsletter.", "description": "A spate of dealmaking suggests high expectations for antibody-drug conjugates", "ogDescription": "A spate of dealmaking suggests high expectations for antibody-drug conjugates", "imageUrl": "https://www.economist.com/media-assets/image/20230923_WBP502.jpg", "imageHeight": 720, "imageWidth": 1280, "datePublished": "2023-09-21T12:51:46Z", "dateModified": "2023-09-21T12:51:48Z", "dateCreated": "2023-09-20T10:54:51Z", "isPrintArticle": true, "printEdition": "2023-09-23T00:00:00Z", "copyrightYear": 2023, "dateline": "New York", "inLanguage": "en", "interactive": false, "scripts": [], "css": []}, "sectionArticles": [{"id": "/content/b4p157fqc1oeop2urucv1cpd4clks1ub", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.48, "__typename": "Content"}, "__typename": "Content"}], "headline": "Abu Dhabi throws a surprise challenger into the AI race", "url": {"canonical": "https://www.economist.com/business/2023/09/21/abu-dhabi-throws-a-surprise-challenger-into-the-ai-race", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/1o2shmegq6c5r1aq48mi068593bb9brb", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.49, "__typename": "Content"}, "__typename": "Content"}], "headline": "California cracks down on carbon", "url": {"canonical": "https://www.economist.com/business/2023/09/21/california-cracks-down-on-carbon", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/2tu5b8a8bd3f8lnhtveg9h5v806igul1", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.51, "__typename": "Content"}, "__typename": "Content"}], "headline": "Big pharma can\u2019t get enough of one class of cancer drugs", "url": {"canonical": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/fh82aprub7qprnmv9tmsv8qket7i8m5g", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.52, "__typename": "Content"}, "__typename": "Content"}], "headline": "Friendships in the office", "url": {"canonical": "https://www.economist.com/business/2023/09/21/friendships-in-the-office", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/2urnd2kkds2latc8pp0tvp8a9ilp7iua", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.53, "__typename": "Content"}, "__typename": "Content"}], "headline": "What Arm and Instacart say about the coming IPO wave", "url": {"canonical": "https://www.economist.com/business/2023/09/21/what-arm-and-instacart-say-about-the-coming-ipo-wave", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/m1k83u2tnumchn33o6reqn0gdpj44cku", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.5, "__typename": "Content"}, "__typename": "Content"}], "headline": "America\u2019s big car firms face lengthy strikes", "url": {"canonical": "https://www.economist.com/business/2023/09/20/americas-big-car-firms-face-lengthy-strikes", "__typename": "URL"}, "__typename": "Content"}, {"id": "/content/opcieuuvk8dt5n5gvsk9r836pgkbu16o", "publication": [{"id": "/content/q7kadojabt8mqss3838etdaslph43q0e", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/3et857aqlkhdb2sjdnaq7cvei52kc0nl", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/kpr5l6d6d2j464ou5bf62rm0rna9vsg6", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/4bq6lktc4ae95v69i85aafs6o870pm2u", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/34hc4rj8qmujur479tl3n4os4616096t", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/dg3g5stcnd95p2l8a25396rfsk62i042", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/lh3aotm59vn5ps1hsnk8t7er5gp3uts5", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}, {"id": "/content/9rk0h3dl3sggbqj9nis863hduia265ve", "context": {"position": 1500.47, "__typename": "Content"}, "__typename": "Content"}], "headline": "Could OpenAI be the next tech giant?", "url": {"canonical": "https://www.economist.com/business/2023/09/18/could-openai-be-the-next-tech-giant", "__typename": "URL"}, "__typename": "Content"}]}